Peifer, Martin
Hertwig, Falk
Roels, Frederik
Dreidax, Daniel
Gartlgruber, Moritz
Menon, Roopika
Krämer, Andrea
Roncaioli, Justin L.
Sand, Frederik
Heuckmann, Johannes M.
Ikram, Fakhera
Schmidt, Rene
Ackermann, Sandra
Engesser, Anne
Kahlert, Yvonne
Vogel, Wenzel
Altmüller, Janine
Nürnberg, Peter
Thierry-Mieg, Jean
Thierry-Mieg, Danielle
Mariappan, Aruljothi
Heynck, Stefanie
Mariotti, Erika
Henrich, Kai-Oliver
Gloeckner, Christian
Bosco, Graziella
Leuschner, Ivo
Schweiger, Michal R.
Savelyeva, Larissa
Watkins, Simon C.
Shao, Chunxuan
Bell, Emma
Höfer, Thomas
Achter, Viktor
Lang, Ulrich
Theissen, Jessica
Volland, Ruth
Saadati, Maral
Eggert, Angelika
de Wilde, Bram
Berthold, Frank
Peng, Zhiyu
Zhao, Chen
Shi, Leming
Ortmann, Monika
Büttner, Reinhard
Perner, Sven
Hero, Barbara
Schramm, Alexander
Schulte, Johannes H.
Herrmann, Carl
O’Sullivan, Roderick J.
Westermann, Frank
Thomas, Roman K.
Fischer, Matthias
Article History
Received: 17 April 2015
Accepted: 22 July 2015
First Online: 14 October 2015
Change Date: 28 October 2015
Change Type: Correction
Change Details: Spelling of author C.G. was corrected.
Competing interests
: M.P. is a co-founder and shareholder of NEO New Oncology, and received consulting fees from NEO New Oncology. R.K.T. is a founder and shareholder of NEO New Oncology, and received consulting and lecture fees from NEO New Oncology, Sanofi-Aventis, Merck, Roche, Lilly, Boehringer Ingelheim, AstraZeneca, Atlas Biolabs, Daiichi Sankyo, Johnson & Johnson, Puma and Clovis, as well as research support from Merck, EOS and AstraZeneca.